ADMA Biologics (NASDAQ:ADMA) Shares Break Above 200-Day Moving Average – Should You Sell?

ADMA Biologics Inc (NASDAQ:ADMA) shares crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $11.13 and traded as high as $11.19. ADMA Biologics shares last traded at $11.17, with a volume of 2,219,170 shares changing hands.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ADMA. Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a report on Monday, September 14th. Mizuho cut their price target on shares of ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating for the company in a report on Wednesday, July 15th. Finally, Zacks Research upgraded ADMA Biologics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, September 2nd. Three analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $18.67.

ADMA Biologics Trading Up 4.2%

The company has a quick ratio of 3.81, a current ratio of 6.97 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $2.63 billion, a P/E ratio of 16.79 and a beta of 0.70. The firm’s 50-day simple moving average is $9.93 and its 200-day simple moving average is $11.10.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 EPS for the quarter, hitting analysts’ consensus estimates of $0.16. ADMA Biologics had a net margin of 32.98% and a return on equity of 40.17%. The firm had revenue of $124.39 million for the quarter, compared to analyst estimates of $125.34 million. During the same quarter in the prior year, the firm earned $0.14 EPS. The business’s revenue for the quarter was up 2.0% compared to the same quarter last year. Analysts anticipate that ADMA Biologics Inc will post 0.78 EPS for the current year.

Institutional Trading of ADMA Biologics

A number of hedge funds have recently bought and sold shares of ADMA. Bridge City Capital LLC bought a new stake in shares of ADMA Biologics during the third quarter valued at approximately $2,665,000. Mirae Asset Global Investments Co. Ltd. bought a new position in ADMA Biologics in the third quarter worth $115,000. Summit Global Investments raised its holdings in ADMA Biologics by 61.9% in the third quarter. Summit Global Investments now owns 29,951 shares of the biotechnology company’s stock worth $300,000 after purchasing an additional 11,446 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in ADMA Biologics by 10.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 40,868 shares of the biotechnology company’s stock valued at $407,000 after buying an additional 3,981 shares during the period. Finally, Pinnacle Wealth Planning Services Inc. lifted its position in ADMA Biologics by 33.1% during the third quarter. Pinnacle Wealth Planning Services Inc. now owns 5,721 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 1,422 shares during the period. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company focused on developing, manufacturing and commercializing plasma-derived biologic products for people with compromised or weakened immune systems. The company’s activities include collecting human plasma, developing immune globulin therapies and manufacturing products for use in the prevention and treatment of certain infectious diseases.

ADMA’s portfolio includes Asceniv, an intravenous immune globulin indicated for primary humoral immunodeficiency disease, and Bivigam, an intravenous immune globulin used for the treatment of primary humoral immunodeficiency.